BPX-01: Phase IIb started

BioPharmX began the double-blind, placebo-controlled, U.S. Phase IIb OPAL trial to evaluate about 1 g of 1% or 2% BPX-01 topical gel once daily for 12 weeks in about 225 patients with moderate to seve...